Medical Journal of Mashhad university of Medical Sciences

Medical Journal of Mashhad university of Medical Sciences

Effect of Oxybutynin on Catheter-Related Bladder Discomfort after Cystoplasty in Placenta Accreta Patients

Document Type : Research Paper

Authors
Amir abbas Asadpour 1
Freshteh Bazmi 2
Zahiroddin Khajeh Karimoddini 3
1 Assistant professor , Urology Department, Ghaem Hospital, Mashhad University of Medical Sciences
2 Gynecologist, Ghaem Hospital, Mashhad University of Medical Sciences
3 Resident of Urology, Ghaem Hospital, Mashhad University of Medical Sciences
10.22038/mjms.2019.14776
Abstract
Abstract
Introduction:In a considerable number of pregnant patients with placenta accreta, during cesarian section bladder involment and injury is common .After bladder repairment, urinary catheterization and free drainage for a long time( about three weeks) is needed. Sondage is a source of significant discomfort in these group of patients . Burn sensation, bladder fullness, urgency, and urine leakage are the most common problems. In this cross-sectional retrograde study, we aimed to describe the incidence and severity of the catheter-related bladder discomfort (CRBD) in patients receiving  oxybutynin as  anticholinergic treatment and whom not received this drug as the control group.
Materials & Methods: In about six years period of time since 2012 to 2018 , forty three patients whom had been visited in Mashhad Ghaem Hospital clinic for their bladder injury follow up ,enrolled in this study .Twenty five  (58.2%) patients had received antibiotics and analgesics as the routine regimen (control group) . In addition to the routine regimen 18 (41.8%) patients had received 5 to 15 mg daily oxybutynin oral tablet (Oxybutynin group). During follow up and after about 21 days, patients were asked and evaluated about the severity of catheter related bladder discomfort (CRBD). Oxybutynin had stopped 48 hours before catheter removal.
Results: In Oxybutynin group, all patients described the severity of CRBD as mild to moderate, whereas in control group, for 19 (76%) patients, CRBD was severe and it was moderate in only 6(24%) patients .The most common complication in oxybutynin group was mouth dryness which was expressed severe by only 3(14.4%)  patients  in the first week of treatment. Mouth Dryness was considerably controlled by decreasing the oxybutynin dose and drinking more liquids and especially chewing gum. Constipation was the second one and limited by using high-fiber foods.
Conclusion: In this study we saw that using oral Oxybutynin tablet as an anticholinergic drug could be beneficial for controlling CRBD after cystoplasty in placenta accreta patients.
Keywords
Oxybutynin
Placenta accreta
Urinary Catheterization

  1. References

    1. Cahill AG, Beigi R, Heine RP, Silver RM, Wax JR. Placenta accreta spectrum. Am J Obstet Gynecol 2018; 219:B2-16.
    2. Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG 2014; 121:62-71.
    3. Oyelese Y, Smulian JC. Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol 2006; 107:927-41.
    4. Bauer ST, Bonanno C. Abnormal placentation. Semin Perinatol 2009; 33:88-96.
    5. Movahedi M, Saeidi M, Derakhshanfar S. Evaluating the frequency distribution of pregnant women with placenta accrete according to some risk factors. J Isfahan Med Sch 2005; 22:115-8.
    6. Hollingsworth JM, Rogers MM, Krein SL, Hickner A, Kuhn L, Cheng A, et al. Determining the noninfectious complications of indwelling urethral catheters: a systematic review and meta-analysis. Ann Intern Med 2013; 159:401-10.
    7. Saint S, Trautner BW, Fowler KE, Colozzi J, Ratz D, Lescinskas E, et al. A multicenter study of patient-reported infectious and noninfectious complications associated with indwelling urethral catheters. JAMA Intern Med 2018; 178:1078-85.
    8. Binhas M, Motamed C, Hawajri N, Yiou R, Marty J. Predictors of catheter-related bladder discomfort in the post-anaesthesia care unit. Ann Fr Anedth Reanim 2011; 30:122-5.
    9. Tauzin-Fin P, Sesay M, Svartz L, Krol-Houdek MC, Maurette P. Sublingual oxybutynin reduces postoperative pain related to indwelling bladder catheter after radical retropubic prostatectomy. Br J Anaesth 2007; 99:572-5.
    10. Agarwal A, Dhiraaj S, Singhal V, Kapoor R, Tandon M. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. Br J Anaesth 2006; 96:377-80.
    11. Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45:253-308.
    12. Hu B, Li C, Pan M, Zhong M, Cao Y, Zhang N, et al. Strategies for the prevention of catheter-related bladder discomfort: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. Medicine 2016; 95:e4859.
    13. Agarwal A, Raza M, Singhal V, Dhiraaj S, Kapoor R, Srivastava A, et al. The efficacy of tolterodine for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. Anesth Analg 2005; 101:1065-7.
    14. Binhas M, Motamed C, Hawajri N, Yiou R, Marty J. Predictors of catheter-related bladder discomfort in the post-anaesthesia care unit. Ann Fr Anesth Reanim 2011; 30:122-5.
    15. Yamanishi T, Chapple C, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J Urol 2001; 19:299-306.
    16. Igawa Y. Discussion: functional role of M1, M2, and M3 muscarinic receptors in overactive bladder. Urology 2000; 85:47-9.
    17. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55:33-46.
    18. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997; 157:1093-7.
    19. Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine–a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997; 327:195-207.
    20. Tauzin-Fin P, Stecken L, Sztark F. Catheter-related bladder discomfort in post-anaesthesia care unit. InAnnales francaises d'anesthesie et de reanimation. Ann Fr Anesth Reanim 2012; 31:605-8.
    21. Hu B, Li C, Pan M, Zhong M, Cao Y, Zhang N, et al. Strategies for the prevention of catheter-related bladder discomfort: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. Medicine 2016; 95:e4859.
    22. Bai Y, Wang X, Li X, Pu C, Yuan H, Tang Y, et al. Management of catheter-related bladder discomfort in patients who underwent elective surgery. J Endourol 2015; 29:640-9.
    23. Uvin P, Boudes M, Menigoz A, Franken J, Pinto S, Gevaert T, et al. Chronic administration of anticholinergics in rats induces a shift from muscarinic to purinergic transmission in the bladder wall. Eur Urol 2013; 64:502-10.
    24. Goldfischer ER, Sand PK, Thomas H, Peters‐Gee J. Efficacy and safety of oxybutynintopical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double‐blind, placebo‐controlled study. Neurourol Urodyn 2015; 34:37-43.
    25. Gittelman M, Weiss H, Seidman L. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. J Urol 2014; 191:1014-21.
    26. Pizzi LT, Talati A, Gemmen E, Dahl NV, Bunz TJ, Sand PK. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder. Pharmacoeconomics 2009; 27:329-39.
    27. Zacchè MM, Srikrishna S, Cardozo L. Novel targeted bladder drug-delivery systems: a review. Res Rep Urol 2015; 7:169-78.
    28. Yokoyama O, Ishiura Y, Nakamura Y, Ohkawa M. Urodynamic effects of intravesical oxybutynin chloride in conscious rats. J Urol 1996; 155:768-71.
Medical Journal of Mashhad university of Medical Sciences
Volume 61, Issue 6
May and June 2019
Pages 1800-1810